Balefire LLC Invests $376,000 in United Therapeutics Corporation $UTHR

Balefire LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,307 shares of the biotechnology company's stock, valued at approximately $376,000.

Other hedge funds have also recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in United Therapeutics in the first quarter worth about $313,000. Allianz Asset Management GmbH raised its position in United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after purchasing an additional 33,254 shares in the last quarter. LPL Financial LLC grew its stake in United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after buying an additional 11,007 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after buying an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in United Therapeutics during the first quarter worth about $227,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 4,000 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $397.88, for a total value of $1,591,520.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $51,724.40. This trade represents a 96.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $400.56, for a total transaction of $9,012,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 155,316 shares of company stock worth $56,440,233 over the last ninety days. Insiders own 10.30% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the topic of several research analyst reports. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research note on Thursday, September 4th. Jefferies Financial Group raised their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Oppenheimer boosted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. Finally, Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $438.85.

United Therapeutics Trading Up 1.4%

Shares of UTHR opened at $403.68 on Thursday. The stock has a market capitalization of $18.21 billion, a P/E ratio of 15.76, a price-to-earnings-growth ratio of 6.07 and a beta of 0.62. The firm's fifty day simple moving average is $324.92 and its two-hundred day simple moving average is $309.23. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the prior year, the company posted $5.85 EPS. United Therapeutics's revenue for the quarter was up 11.7% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.